• AbbVie launched a USD 10 billion multi-tranche senior notes offering, including USD 500 million senior floating rate notes due 2028.
• Tranches include fixed-rate senior notes due 2028, 2030, 2031, 2033, 2036, 2038, 2056, 2066 with coupons from 4.5% to 6.1%.
• Net proceeds expected at about USD 9.93 billion; funding part of cash obligations for the Apogee Therapeutics acquisition.
• Remaining proceeds earmarked for general corporate purposes, including potential debt repayment or repurchase.
• Closing targeted for Aug. 18, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-091269), on August 05, 2026, and is solely responsible for the information contained therein.